China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
China alone, the market is expected to grow to 14.9 billion yuan ($2 billion) by 2030. The approval is potentially paving the way for off-label use of Tirzepatide for weight loss, similar to Wegvoy.
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the ...
Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes. Tirzepatide, a novel dual agonist at both the GLP-1 and the glucose-dependent ...
Eli Lilly & Co. will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...
(Bloomberg) -- Novo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as ...
Eli Lilly & Co. will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...
Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market ...
, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk (NOVOb.CO ...
Shares of the drugmaker were up 3.2% in early trading. Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are ...